• Consensus Rating: N/A
  • Consensus Price Target: GBX 0
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
GBX 26
▼ -1 (-3.70%)

This chart shows the closing price for VAL by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New ValiRx Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for VAL and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for VAL

Analyst Price Target is GBX 0
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for ValiRx in the last 3 months. The average price target is GBX 0, with a high forecast of GBX 0 and a low forecast of £100,000. The average price target represents a -100.00% upside from the last price of GBX 26.

This chart shows the closing price for VAL for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is N/A

The current consensus among 0 investment analysts is to n/a stock in ValiRx. This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/5/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/4/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/2/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/31/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/31/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/29/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/28/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/27/2021

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
1/12/2018Beaufort SecuritiesReiterated RatingSpeculative Buy
12/19/2017Beaufort SecuritiesReiterated RatingSpeculative Buy
11/16/2017Beaufort SecuritiesReiterated RatingSpeculative BuyGBX 6.50
10/13/2017Beaufort SecuritiesReiterated RatingSpeculative BuyGBX 6.50
9/27/2017Beaufort SecuritiesReiterated RatingSpeculative BuyGBX 6.50
9/8/2017Beaufort SecuritiesReiterated RatingSpeculative BuyGBX 6.50
7/31/2017Beaufort SecuritiesReiterated RatingSpeculative BuyGBX 6.50
6/16/2017Beaufort SecuritiesReiterated RatingSpeculative BuyGBX 6.50
5/25/2017Beaufort SecuritiesReiterated RatingSpeculative BuyGBX 6.50
5/15/2017Beaufort SecuritiesReiterated RatingSpeculative BuyGBX 6.50
5/8/2017Beaufort SecuritiesReiterated RatingSpeculative BuyGBX 6.50
3/10/2017Beaufort SecuritiesReiterated RatingSpeculative BuyGBX 6
3/1/2017Beaufort SecuritiesReiterated RatingSpeculative Buy
1/12/2017Beaufort SecuritiesReiterated RatingSpeculative Buy
12/9/2016Beaufort SecuritiesReiterated RatingSpeculative Buy
12/8/2016Northland SecuritiesReiterated RatingCorporate
11/30/2016Beaufort SecuritiesReiterated RatingSpeculative Buy
11/29/2016Northland SecuritiesReiterated RatingCorporate
11/3/2016Northland SecuritiesReiterated RatingCorporate
10/26/2016Beaufort SecuritiesReiterated RatingSpeculative Buy
10/13/2016Northland SecuritiesReiterated RatingCorporate
9/28/2016Beaufort SecuritiesReiterated RatingSpeculative Buy
9/27/2016Northland SecuritiesReiterated RatingCorporate
(Data available from 9/27/2016 forward)

News Sentiment Rating

0.03 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/1/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/31/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/30/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/30/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/29/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/29/2021
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/28/2021
  • 1 very positive mentions
  • 1 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
9/27/2021

Current Sentiment

  • 1 very positive mentions
  • 1 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
ValiRx logo
ValiRx plc, a biotechnology oncology focused company, engages in developing novel therapeutics and associated biomarkers for cancer in the United Kingdom. The company's lead drug candidates include VAL201, an anti-cancer therapeutic that is in Phase I/II trials for the treatment of prostate cancer and other indications of hormone induced unregulated growth, including endometriosis; VAL301, a reformulation of VAL201, which is in pre-clinical development for the treatment of women with endometriosis; and VAL401, a reformulation of generic drug Risperidone, which has completed Phase II clinical trial for the treatment of non-small cell lung cancer. Its drug candidates also comprise VAL101, a candidate produced by GeneICE technology platform to modulate BCl2 expression Â- implicated in cancers. ValiRx plc has collaboration agreement with Oncolytika Limited and Black Cat Bio Limited to develop and evaluate BC201 for patients suffering a hyperimmune response to Coronavirus SARS-CoV2 infection. The company was incorporated in 2000 and is based in Hatfield, the United Kingdom.
Read More

Today's Range

Now: GBX 26
Low: 25.35
High: 27.40

50 Day Range

MA: GBX 20.94
Low: 17.74
High: 29.50

52 Week Range

Now: GBX 26
Low: 17.26
High: 73

Volume

672,968 shs

Average Volume

816,844 shs

Market Capitalization

£16.91 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of ValiRx?

The following equities research analysts have issued stock ratings on ValiRx in the last twelve months:
View the latest analyst ratings for VAL.

What is the current price target for ValiRx?

0 Wall Street analysts have set twelve-month price targets for ValiRx in the last year. has the lowest price target set, forecasting a price of £100,000 for ValiRx in the next year.
View the latest price targets for VAL.

What is the current consensus analyst rating for ValiRx?

ValiRx currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for VAL.

How do I contact ValiRx's investor relations team?

ValiRx's physical mailing address is 3rd Fl, 16 Upper Woburn Place, LONDON, WC1H 0BS, United Kingdom. The company's listed phone number is +44-20-30084416. The official website for ValiRx is www.valirx.com.